This post has been archived and contains information that may be out of date.
Update on Monoclonal Antibody Therapy Authorized for Emergency UseOn Nov. 9, the Food and Drug Administration granted emergency use authorization (EUA) to a monoclonal antibody therapy called bamlanivimab, produced by Eli Lilly and Company, for the treatment of mild to moderate COVID-19. The federal government has purchased 320,000 doses through the end of 2020; the...
This content is restricted to members.